Stockreport

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon, Inc. - common stock  (ANNX) 
PDF Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (B [Read more]